
Cellectis in offering of US$175m ADS following asset swap
Underwriters will have a 30-day over-allotment option to purchase up to 15% of the aggregate offering size. Goldman Sachs & Co. LLC and Citigroup...

MYR Pharma completes chronic hepatitis delta POC trial
In February, the company had announced that Myrcludex B + interferon treatment was well tolerated by 60 patients with chronic hepatitis D during the...

Algorithm tracks cancer type down to methylation pattern
The group headed by Stefan Pfister at German Cancer Research Center (Heidelberg) reported in Nature that the availability of their method...

Takeda announced bid for Shire
In a press release Shire said it has not received an official approach from Takeda. Following on the take-over rumours, Shire announced it achieved...

New target could minimise transplant risks
Intestinal GVHD, in which donor T cells attack host tissue, is associated with a poor prognosis. A research group headed by Kai Hildner at University...

FIND funding diagnostics to fight AMR
Geneva-based Foundation for Innovative New Diagnostics (FIND), which already supports collaborations with more than 150 partners to fight...

Cullinan Oncology partners with MAB Discovery
The companies said they will use MAB Discovery ’s rabbit platform to generate a potent, human immune checkpoint agonist. Last October,...